Literature DB >> 8258622

Interleukin-6 and interleukin-1 alpha production is associated with antigen-induced late nasal response.

P Gosset1, F Malaquin, Y Delneste, B Wallaert, A Capron, M Joseph, A B Tonnel.   

Abstract

BACKGROUND: Cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 alpha, IL-6 and granulocyte macrophage-colony stimulating factor (GM-CSF) are able to potentiate allergic inflammation and seem to be implicated in the development of the late allergic reaction.
METHODS: To study the time course of cytokine production, sequential lavages were performed after nasal allergen challenge. Thirteen patients with allergic rhinitis and four healthy subjects were exposed to grass pollen (n = 6 and n = 2, respectively) or dust mite allergen (n = 7 and n = 2, respectively).
RESULTS: Among the patients with allergic rhinitis, a single early response (single responders) developed in four, eight exhibited a dual response (dual responders) and one patient as well as the four healthy subjects did not respond. In addition to the measurement of IL-1 alpha, IL-6, TNF-alpha and GM-CSF concentrations by ELISA, the release of histamine, tryptase, and eosinophil cationic protein was also evaluated by radioimmunoassay performed on nasal lavage fluids. Concerning mediator levels in nasal lavage fluid, neither histamine release nor cytokine elevation were noted in healthy subjects. As previously described, histamine, tryptase and eosinophil cationic protein were released in single and dual responders. Concerning cytokines, TNF-alpha was undetectable in the majority of nasal lavages and an increase in GM-CSF concentration was occasionally observed whatever the type of response. In contrast, an increase in IL-1 alpha and IL-6 levels was observed for dual responders during the early period (12.6 +/- 3 and 9.2 +/- 2 pg/ml, respectively; p < 0.01 in both cases) and at a higher level during the late period (14.5 +/- 4, p not significant and 16.7 +/- 8 pg/ml, respectively; p < 0.01) when compared with baseline values (7.2 +/- 2.2 and 2 +/- 0.7 pg/ml, respectively). For single responders IL-1 alpha and IL-6 secretion was detected mainly during the early period.
CONCLUSION: These data suggest a role for IL-1 alpha in the induction and perennisation of the inflammatory reaction in allergic rhinitis, whereas the role of IL-6 remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8258622     DOI: 10.1016/0091-6749(93)90066-o

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  7 in total

Review 1.  Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies.

Authors:  Manuel A R Ferreira
Journal:  Mediators Inflamm       Date:  2003-10       Impact factor: 4.711

2.  Histamine induces IL-6 production by human endothelial cells.

Authors:  Y Delneste; P Lassalle; P Jeannin; M Joseph; A B Tonnel; P Gosset
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

Review 3.  Mechanisms of allergic rhinitis.

Authors:  J N Baraniuk
Journal:  Curr Allergy Asthma Rep       Date:  2001-05       Impact factor: 4.919

Review 4.  Hyperresponsiveness in the human nasal airway: new targets for the treatment of allergic airway disease.

Authors:  P J Turner; J C Foreman
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

5.  Histamine Promotes the Release of Interleukin-6 via the H1R/p38 and NF-κB Pathways in Nasal Fibroblasts.

Authors:  Il-Ho Park; Ji-Young Um; Jung-Sun Cho; Seung Hoon Lee; Sang Hag Lee; Heung-Man Lee
Journal:  Allergy Asthma Immunol Res       Date:  2014-07-28       Impact factor: 5.764

6.  Tumour necrosis factor-alpha in nasal allergy.

Authors:  K Hisamatsu; T Ganbo; T Nakazawa; T Nakajima; J Ko; R Goto; Y Murakami; K Misui
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

Review 7.  Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications.

Authors:  M H Smolensky; A Reinberg; G Labrecque
Journal:  J Allergy Clin Immunol       Date:  1995-05       Impact factor: 10.793

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.